71 results about "Selectin" patented technology

The invention discloses a functional hydrogel microsphere and a preparation method and application thereof, and relates to the technical field of medicines.The preparation method comprises the steps that a hyaluronic acid methacrylic acid precursor solution and an IL-1beta shRNA adenovirus stock solution are mixed to obtain an Ad-atHAMA precursor solution; preparing the Ad (at) HAMA precursor solution through an oil-in-water micro-fluidic technology to obtain an Ad (at) HAMA microsphere; and sequentially adding the Ad (at) HAMA microspheres, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and N-hydroxysuccinimide into a 2-morpholinoethanesulfonic acid buffer solution, carrying out activating treatment, adding E selectin, and incubating to obtain the functionalized hydrogel microspheres. The functionalized hydrogel microspheres can inhibit a related mechanism of acute spinal cord injury pathological progress and promote neural function repair by targeting adsorption of neutrophil to regulate Nets-triggered innate immune inflammation cascade.

The invention relates to the technical field of biological medicine, in particular to a cerium oxide nano-enzyme delivery system based on carried neutrophil, and the system comprises cerium oxide nano-particles; the surfaces of the cerium oxide nanoparticles are coated with the lipoic acid zwitterionic polymer layers; the sialic acid molecules and the protocatechuic aldehyde molecules are modified on the surface of the lipoic acid zwitterionic polymer layer; wherein the system realizes breakthrough of a blood brain barrier and precise delivery of ischemic lesions through mediation targeting delivery of L-selectin on the surface of neutrophile granulocyte, and based on a cerium oxide nano-enzyme delivery system carrying neutrophile granulocyte, a'antioxidation-anti-inflammation-angiogenesis promotion-neural restoration 'quadruple synergistic mechanism is integrated, so that the system has the advantages that the system is simple in structure and convenient to use, and the application prospect is wide. And a new strategy of multi-target intervention is provided for cerebral arterial thrombosis treatment.

Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.

The present disclosure provides a soluble P-selectin (sP-sel) interfering the interaction between stem cells and niches to mobilize stem cells from bone marrow. The mobilization of stem cells with sP-sel can treat a subject in need of preservation, repair, or regeneration of a tissue, or revascularization.

The invention relates to a ligand targeting neutrophil and neurons as well as a preparation method and application of the ligand. The ligand for targeting the neutrophil and the neuron is prepared from the following raw materials in parts by weight: 30 to 50 parts of DSPE-PEG-Tet1, 2 to 3 parts of ketal thiol with carboxyl groups at two ends and 30 to 50 parts of a neutrophil targeting ligand, the neutrophil targeting ligand is one or more of sialic acid, an anti-CD66b antibody, an anti-CD177 antibody, an anti-CD16b antibody, N-formylmethionine peptide (fMLF) and an analogue thereof, a CXCR1 / CXCR2 binding peptide, an integrin binding peptide, a selectin ligand and lectin. According to the invention, sequential targeting of neutrophile granulocytes-neurons can be realized, target cells of ischemic lesions can be accurately protected, and the improvement effect on the cerebral infarction area of MCAO rats can be obviously enhanced.

The invention provides a method for evaluating effective cell functions in thymus tissue based on multi-factor combination, which comprises the following steps: detecting the content of molecular markers in thymus tissue slice culture supernatant, the molecular markers being one or a combination of more of IL16, L-Selectin, CCL19, CCL21, CXCL16 and CXCL12, and the content of the molecular markers being one or more of IL16, L-Selectin, CCL19, CCL21, CXCL16 and CXCL12. The combination of one or more of IL16 and L-Selectin is used for evaluating the effective cell function of the thymus tissue raw material, and the combination of one or more of CCL19, CCL21, CXCL16 and CXCL12 is used for evaluating the effective cell function of the thymus tissue slice finished product. The thymus tissue slice does not need to be lost, the consumed time is short, and the functions of effective cells in the thymus tissue slice can be accurately reflected.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.

The present invention discloses a targeted microwave-responsive nanobody and a preparation method and application thereof. The targeted microwave-responsive nanobody is based on a metal organic framework, on which paclitaxel and ionic liquid are adsorbed, and on which the surface of the base framework is modified with polydopamine, on which fucoidan is connected. The metal organic framework is used, the advantages of inorganic materials and organic compounds are combined, and the surface is modified with fucoidan to target P-selectin to achieve multiple targeting. The inner core is loaded with ionic liquid as a sensitizing material to enhance the microwave response capability, thereby providing a unique solution for local microwave treatment combined with chemotherapy for prostate cancer, and therefore has good potential.

The present invention relates to a fluorescent probe based on a lanthanide metal organic framework, a preparation method and an application, and belongs to the field of nanomaterial technology. The fluorescent probe provided by the present invention is obtained by covalently cross-linking a lanthanide metal organic framework with a neutrophil elastin binding peptide and a P-selectin binding peptide, and the surface of the lanthanide metal organic framework is modified with a tetracyclic antibiotic and arginine. The fluorescent probe prepared by the present invention specifically targets activated platelets and neutrophils, does not affect cell survival rate, does not cause hemolysis of red blood cells, and can be applied to the preparation of diagnostic products for thrombotic diseases. The use of a fluorescent probe loaded with urokinase achieves stable and efficient delivery of urokinase, inhibits platelet aggregation, slows down blood clot contraction, has a good thrombolytic effect, and has the potential to be used in the preparation of drugs for the treatment of thrombotic diseases. The materials required for the present invention are easy to obtain, the preparation method is simple, and a new method is provided for the diagnosis and treatment of thrombotic diseases.

The present invention discloses a platelet-targeting peptide conjugated iridium oxide nanoparticle and its preparation method and application. The structural formula of the nanoparticle is as follows: IrO x -P; wherein, P represents a P-selectin targeting peptide, and the amino acid sequence is as shown in SEQ ID No.1; IrO x -P, in which Ir 3+ and Ir 4+ coexist. The IrO x -P nanoparticles provided by the present invention utilize photothermal-induced vascular damage to achieve secondary enrichment of IrO x -P, realizing the combined and highly efficient treatment of PTT and ferroptosis, while reducing the side effects brought by PTT. In addition, IrO x -P can achieve oxidation-enhanced photoacoustic imaging, which will provide new ideas and methods for tumor-targeted diagnosis and treatment integration.

The inventors' primary objective was to provide a technology for screening materials that can suppress inflammation, particularly in aging tissues. [Solution] The above problem can be solved by a method that includes step B: contacting vascular endothelial cells that have been passaged 15 or more times with a test substance, and step C: evaluating the expression level of at least one inflammation-related factor selected from the group consisting of IL-6, IL-8, CXCL1, PAI-1, MMP-1, ICAM-1, VCAM-1, E-selectin, and CCL2 in the vascular endothelial cells that were contacted with the test substance in step B.

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

The application discloses a cerebrospinal fluid auxiliary diagnosis marker for neuropsychiatric lupus, and relates to the application of any one or more of TCN2, CST6, Trappin-2 and L-selectin as a diagnosis marker in the preparation of a cerebrospinal fluid auxiliary diagnosis reagent for neuropsychiatric lupus. The application provides four biomarkers of TCN2, etc. with high specificity and high sensitivity for diagnosing neuropsychiatric lupus, fills the blank in the field, further improves the accuracy of diagnosis, helps to realize timely early warning in clinic, and helps to establish a new clinical diagnosis standard for lupus encephalopathy.

Embodiments relate to a method comprising (a) expressing a vector comprising a PSGL-1 (P-selectin glycoprotein ligand-1) or a mutant thereof in a VPC (virus producing cell); and blocking a virus infection by inactivating an infectivity of a released virions from the VPC; or (b) expressing a glycoprotein or a mutant thereof in the VPC; blocking the virus infection by preventing binding of the released virions to a target cell; inactivating infectivity of the released virions; and targeting a viral infection. Other embodiments relate to (1) a broad-spectrum anti-viral product comprising: a vector expressing a glycoprotein or a mutant thereof in a VPC; and blocking a virus infection by inactivating infectivity of a released virion from the VPC; and (2) a vaccine comprising a viral particle is configured to a live attenuated or an inactivated or a non-infectious, wherein the viral particle are produced in a VPC.

A method for preparing or using microfluidic chip for detecting or screening peritoneal metastatic cells is provided, comprising the steps of: providing a microfluidic chip having a channel coated with P-selectin; pre-washing the channel with a pre-washing buffer; withdrawing a sample with an adhesion buffer under a negative pressure or suction; washing the channel by withdrawing a washing buffer to separate any non-adhered cells from the channel under a negative pressure or suction; and recovering any adhered cells by withdrawing a recovering buffer under a negative pressure or suction, such that metastatic cells are obtained. The methods and systems provide accessible and effective solutions that help combat cancer and improve patient conditions.

This invention discloses a reactive oxygen species (ROS)-responsive nanocomposite for targeting and repairing damaged endothelium, its preparation, and its application, belonging to the field of nanomedicine technology. The nanocomposite comprises a physalicylate-copper nanoparticle core and a P-selectin-targeting polypeptide linked to the core surface via thiol-copper affinity. The physalicylate-copper nanoparticle core is prepared by coordination of physalicylate and copper ions to form a primary complex, followed by ascorbic acid reduction. This composite nanosystem can specifically recognize and accumulate in the blood vessels and peritubular regions of the kidney injury area, releasing Cu in response to high concentrations of ROS in an inflammatory environment. 2+ Together with HBT, it simultaneously achieves antioxidant and anti-inflammatory functions, promotes angiogenesis and repair, and inhibits the release of inflammatory factors and macrophage infiltration and activation, effectively blocking the fibrosis process. This system has a well-defined structure and strong targeting, and can effectively rebuild microvessels, reduce inflammation, and block the process of renal fibrosis, providing a highly efficient and precise new nanomedicine strategy for the anti-fibrotic treatment of kidney diseases.

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

There is provided a compound of formula (I), and pharmaceutically acceptable salts thereof. This compound can be used as a medicament for example for the prevention or treatment of hyperinflammation, for example lung or respiratory hyperinflammation, or for the prevention or treatment of SIRS, for example SIRS caused by sepsis. (I)

The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3Kα inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3Kα) inhibitors and are therefore useful for the treatment and / or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.

Disclosed herein are methods of mobilizing hematopoietic stem and progenitor cells (HSPC) in a subject in need thereof, the methods include administering one or both of (1) an inhibitor of the polymerization of hemoglobin S and (2) a P-selectin or E-selectin inhibitor, prior to administering a hematopoietic stem cell mobilizing agent.

A recombinant natural killer (NK)-92 cell transfected with a nucleic acid and gamma (γ) irradiated, wherein the nucleic acid encodes: a homing receptor and / or cytokine; an antigen binding protein or c

Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.

Disclosed herein are glyco-decoy acceptor compositions that sidetrack or inhibit the activity of biosynthetic enzymes participating in synthesis of ligands binding at selectin, galectin and siglecs receptors; methods of their preparation and uses in drug discovery and in treatments of diseases.

A method of treating brain-metastasized cancer in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically decreases an amount and / or activity of P-selectin and an immunomodulatory agent. Methods of treating additional cancers are also disclosed.

A method for treating brain metastasis cancer in a subject in need of such treatment is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent that specifically reduces the amount and / or activity of P-selectin and an immunomodulatory agent. Additional methods for treating cancer are also disclosed.

The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.

Intracerebral hemorrhage (ICH), defined as spontaneous bleeding into the brain, is the deadliest, most disabling, and least treatable form of stroke. The aim of the present invention is to generate large amount of hemostatic mEVs to be used as hemostatic patches in different preclinical models of ICH. Indeed, the exogenous mEVs pf the present invention bearing TF and PSGL-1 improve outcome after collagenase-induced ICH by acting as intravascular hemostatic patches. The present invention thus relates to monocyte extracellular vesicles (mEVs) functionalized with tissue factor (TF) and P-Selectin Glycoprotein Ligand 1 (PSGL-1).

The present disclosure relates to polypeptides and variants capable of binding to selectin molecules such as P-selectin, E-selectin, or both.

To provide methods of treating cancer.SOLUTION: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, where the antibodies inhibit PSGL-1 binding to VISTA at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.SELECTED DRAWING: Figure 5